Cyclin-dependent kinase 4-cyclin D1 complex (CDK4-cyclin D1) (CDK4-cyclin D1)

The Cyclin-dependent kinase 4-cyclin D1 complex (CDK4-cyclin D1) is a pivotal regulator of the mammalian cell cycle, specifically governing the transition from the G1 phase to the S phase [2, 7]. This holoenzyme consists of the catalytic subunit CDK4, a serine/threonine kinase, and its regulatory partner, cyclin D1 [3, 11]. Its primary canonical function is the site-specific phosphorylation of the retinoblastoma (Rb) protein, which leads to the release of E2F transcription factors and the subsequent expression of genes required for DNA replication [2, 8, 9]. In many human malignancies, the CDK4-cyclin D1 pathway is hyperactivated through mechanisms such as CCND1 gene amplification, CDK4 overexpression, or the loss of endogenous inhibitors like p16INK4A [5, 7, 13]. This dysregulation drives uncontrolled cell proliferation, making the complex a high-priority therapeutic target in oncology [3, 7]. Selective CDK4/6 inhibitors, including palbociclib, ribociclib, and abemaciclib, have been developed to block this kinase activity and are currently used to treat advanced hormone receptor-positive breast cancer [1, 5]. While effective, these therapies are often associated with manageable side effects such as neutropenia and gastrointestinal distress [1, 5].

Other names

CDK4/CCND1 complexCyclin D1-CDK4 complexG1/S-specific cyclin-D1-CDK4 complexCyclin D1-CDK4 holoenzyme

Selective inhibition of the CDK4 kinase activity within the complex, which prevents the phosphorylation of the retinoblastoma (Rb) protein, thereby blocking the transition from the G1 to the S phase of the cell cycle and inducing cell cycle arrest in Rb-proficient cells.